Evidence map›Paper›PMID 25326496›Full record

ArticleNeuro-oncology2015

Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma.

Janardan P Pandey, Emily Kistner-Griffin, Faisal F Radwan, Navtej Kaur, Aryan M Namboodiri, Laurel Black, Mary Ann Butler, Tania Carreon, Avima M Ruder

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Janardan P PandeyDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Emily Kistner-GriffinDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Faisal F RadwanDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Navtej KaurDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Aryan M NamboodiriDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Laurel BlackDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Mary Ann ButlerDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Tania CarreonDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
Avima M RuderDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina (J.P.P., F.F.R., N.K., A.M.N., L.B.); Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (E.K-G.); Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Cincinnati, Ohio (M.A.B., T.C., A.M.R.).
National Institute for Occupational Safety and Health · USMedical University of South Carolina · USCenters for Disease Control and Prevention · US

Funding

Genetic Modifiers of Immune Evasion by Cytomegalovirus in GlioblastomaR21NS078545 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PANDEY, JANARDAN P · 2012 to 2013
$399k
NINDS NIH HHS NS078545
6 · The paper itself

Abstract

backgroundImmunoglobulin γ marker (GM) and κ marker (KM) allotypes, hereditary antigenic determinants of γ and κ chains, respectively, have been shown to be associated with immunity to a variety of self and nonself antigens, but their possible contribution to immunity to the tumor-associated antigens epidermal growth factor receptor (EGFR) and EGFR variant (v)III has not been evaluated. The aim of the present investigation was to determine whether the interindividual variation in endogenous antibody responsiveness to EGFR and EGFRvIII is associated with particular GM, KM, and Fcγ receptor (FcγR) genotypes and whether antibody levels were associated with the overall survival of patients with glioblastoma.

methodsA total of 126 Caucasian participants with glioblastoma were genotyped for several GM, KM, and FcγR alleles and characterized for IgG antibodies to EGFR and EGFRvIII antigens.

resultsThe anti-EGFR antibody levels associated with GM 3/3 homozygotes and GM 3/17 heterozygotes were similar (15.9 vs 16.4 arbitrary units [AU]/µL) and significantly lower than those associated with GM 17/17 homozygotes (19.6 AU/µL; nominal P = .007). Participants homozygous for the GM 21 allele also had significantly higher levels of anti-EGFR antibodies than GM 5/5 homozygotes and GM 5/21 heterozygotes (20.1 vs 16.0 and 16.3 AU/µL; nominal P = .005). Similar associations were found with immune responsiveness to EGFRvIII. Higher anti-EGFR and anti-EGFRvIII antibody levels were associated with enhanced overall survival (16 vs 11 mo, nominal P = .038 and 20 vs 11 mo, nominal P = .004, respectively).

conclusionsGM allotypes contribute to humoral immunity to EGFR in glioblastoma.

Indexed as

AdolescentAdultAgedErbB ReceptorsFemaleGenotypeGlioblastomaHumansImmunoglobulin Gm AllotypesImmunoglobulin Km AllotypesMaleMiddle AgedReceptors, IgGSurvivalYoung AdultErbB ReceptorsImmunoglobulin Gm AllotypesImmunoglobulin Km AllotypesReceptors, IgGantibodyEGFREGFRvIIIglioblastomaGM allotypes

Identifiers

PMID25326496
PMCPMC4482853
OpenAlexW1975408139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.